Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial.

N C Cutter1, D D Scott, J C Johnson

  • 1University of Colorado Health Sciences Center, Denver, USA.

Archives of Physical Medicine and Rehabilitation
|February 11, 2000
PubMed
Summary

Gabapentin effectively reduced spasticity in multiple sclerosis patients, improving both self-reported symptoms and physician assessments. This treatment did not negatively impact concentration or increase fatigue.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Symposium on Pellagra.

Buffalo medical journal·2023
Same author

Some Observations on Gastric and Duodenal Ulcer.

Buffalo medical journal·2023
Same author

Antikamnia.

The Southern medical record·2022
Same author

The Real and Relative Value of Our Recent Antipyretics.

Atlanta medical and surgical journal (1884)·2022
Same author

Perinatal fluoxetine exposure results in social deficits and reduced monoamine oxidase gene expression in mice.

Brain research·2019
Same author

Incidence of variations in human cadaveric renal vessels.

Folia morphologica·2017

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Trials

Background:

  • Spasticity is a common and disabling symptom in multiple sclerosis (MS).
  • Current treatments for MS-related spasticity have limitations and potential side effects.
  • Gabapentin is an anticonvulsant medication with potential for managing neuropathic pain and spasticity.

Purpose of the Study:

  • To evaluate the efficacy of gabapentin in reducing spasticity in individuals with multiple sclerosis (MS).
  • To assess the impact of gabapentin on both subjective patient reports and objective physician-administered spasticity measures.
  • To determine if gabapentin affects cognitive function or fatigue levels in MS patients.

Main Methods:

  • A prospective, double-masked, placebo-controlled, crossover study was conducted.

Related Experiment Videos

  • Participants received either 900 mg of gabapentin three times daily or a placebo for a defined period, followed by a washout and crossover.
  • Spasticity was assessed using various self-report scales (e.g., spasm severity, interference with function) and physician-administered scales (e.g., Modified Ashworth Scale, plantar stimulation response).

    • Main Results:

    • Gabapentin demonstrated a statistically significant reduction in spasticity compared to placebo.
    • Improvements were observed across multiple self-report scales and physician-administered measures, including spasm severity and Modified Ashworth Scale.
    • No significant adverse effects on concentration (Digit Span, Digit Symbol) or fatigue were detected.

    Conclusions:

    • Gabapentin is an effective treatment for reducing spasticity in multiple sclerosis patients.
    • The medication offers benefits without exacerbating cognitive impairment or fatigue.
    • Gabapentin represents a viable therapeutic option for managing MS-related spasticity.